转移性-话题@MedSci

#转移性#

975篇内容 | 3419人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1386636, encodeId=67dc13866361b, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=PD-L1单抗Bavencio：正在欧洲接受审查以治疗转移性尿路上皮癌, objectType=article, longId=196293, objectId=15011962937c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15011962937c, replyNumber=0, likeNumber=60, createdTime=2020-06-24, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15011962937c, moduleTitle=PD-L1单抗Bavencio：正在欧洲接受审查以治疗转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15011962937c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386635, encodeId=2490138663554, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Fruquintinib治疗转移性结直肠癌：美国FDA授予快速通道称号, objectType=article, longId=196107, objectId=b8dd19610eb8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8dd19610eb8, replyNumber=0, likeNumber=0, createdTime=2020-06-20, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8dd19610eb8, moduleTitle=Fruquintinib治疗转移性结直肠癌：美国FDA授予快速通道称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8dd19610eb8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386634, encodeId=0da013866343d, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=FDA授予伊立替康脂质体（ONIVYDE）快速通道指定，用于转移性胰腺癌的一线联合治疗, objectType=article, longId=196066, objectId=8dab1960666a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dab1960666a, replyNumber=0, likeNumber=75, createdTime=2020-06-19, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dab1960666a, moduleTitle=FDA授予伊立替康脂质体（ONIVYDE）快速通道指定，用于转移性胰腺癌的一线联合治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dab1960666a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386633, encodeId=70361386633c3, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=转移性小细胞肺癌（SCLC）新药Zepzelca（lurbinectin）已获批准, objectType=article, longId=196011, objectId=01331960112d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01331960112d, replyNumber=0, likeNumber=77, createdTime=2020-06-18, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01331960112d, moduleTitle=转移性小细胞肺癌（SCLC）新药Zepzelca（lurbinectin）已获批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01331960112d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386632, encodeId=3f83138663244, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Zepzelca在美国获批，二线治疗转移性小细胞肺癌, objectType=article, longId=195956, objectId=6c89195956f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c89195956f1, replyNumber=0, likeNumber=64, createdTime=2020-06-18, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c89195956f1, moduleTitle=Zepzelca在美国获批，二线治疗转移性小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c89195956f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386631, encodeId=ee77138663124, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=罗氏的Tecentriq/Avastin组合获得美国批准——用于无法切除或转移性肝癌的免疫疗法, objectType=article, longId=195322, objectId=25f219532272, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25f219532272, replyNumber=0, likeNumber=72, createdTime=2020-06-06, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25f219532272, moduleTitle=罗氏的Tecentriq/Avastin组合获得美国批准——用于无法切除或转移性肝癌的免疫疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25f219532272)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386630, encodeId=e7271386630c5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=FDA批准CYRAMZA（ramucirumab）一线治疗转移性EGFR突变非小细胞肺癌, objectType=article, longId=195114, objectId=ab2419511413, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab2419511413, replyNumber=0, likeNumber=73, createdTime=2020-06-03, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab2419511413, moduleTitle=FDA批准CYRAMZA（ramucirumab）一线治疗转移性EGFR突变非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab2419511413)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386629, encodeId=4cfe138662948, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=NEJM：奥拉帕尼治疗转移性去势耐药性前列腺癌, objectType=article, longId=194921, objectId=7e4c194921ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e4c194921ab, replyNumber=0, likeNumber=72, createdTime=2020-05-30, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e4c194921ab, moduleTitle=NEJM：奥拉帕尼治疗转移性去势耐药性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e4c194921ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386628, encodeId=500d1386628ee, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Brit J Cancer：性别在转移性结直肠癌先天性和适应性免疫微环境中的作用, objectType=article, longId=194782, objectId=703f194e8205, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=703f194e8205, replyNumber=0, likeNumber=110, createdTime=2020-05-28, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=703f194e8205, moduleTitle=Brit J Cancer：性别在转移性结直肠癌先天性和适应性免疫微环境中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=703f194e8205)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386627, encodeId=3593138662ec1, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet Oncol：派姆单抗联合疗法一线治疗HER2阳性转移性食管胃癌, objectType=article, longId=194729, objectId=8973194e294c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8973194e294c, replyNumber=0, likeNumber=83, createdTime=2020-05-27, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8973194e294c, moduleTitle=Lancet Oncol：派姆单抗联合疗法一线治疗HER2阳性转移性食管胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8973194e294c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386626, encodeId=f0eb138662673, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者, objectType=article, longId=194626, objectId=133519462630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=133519462630, replyNumber=0, likeNumber=86, createdTime=2020-05-25, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=133519462630, moduleTitle=FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=133519462630)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386625, encodeId=49fa1386625df, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, objectType=article, longId=194432, objectId=19de1944327b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19de1944327b, replyNumber=0, likeNumber=68, createdTime=2020-05-21, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19de1944327b, moduleTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19de1944327b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386624, encodeId=f009138662416, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=肺癌一线免疫治疗！BMS明星免疫组合Opdivo+Yervoy获美国FDA批准第5个适应症，治疗转移性非小细胞肺癌患者!, objectType=article, longId=194364, objectId=22021943645c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22021943645c, replyNumber=0, likeNumber=68, createdTime=2020-05-20, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22021943645c, moduleTitle=肺癌一线免疫治疗！BMS明星免疫组合Opdivo+Yervoy获美国FDA批准第5个适应症，治疗转移性非小细胞肺癌患者!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22021943645c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386623, encodeId=57c31386623ab, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet：Atezolizumab联合铂化疗一线治疗转移性尿路上皮癌, objectType=article, longId=194245, objectId=b6fe19424555, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6fe19424555, replyNumber=0, likeNumber=54, createdTime=2020-05-17, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6fe19424555, moduleTitle=Lancet：Atezolizumab联合铂化疗一线治疗转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6fe19424555)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386622, encodeId=da9b138662284, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=CheckMate -9LA临床试验数据积极！欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗显著提高一线转移性非小细胞肺癌患者总生存, objectType=article, longId=194157, objectId=c3b319415e0d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3b319415e0d, replyNumber=0, likeNumber=52, createdTime=2020-05-16, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3b319415e0d, moduleTitle=CheckMate -9LA临床试验数据积极！欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗显著提高一线转移性非小细胞肺癌患者总生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3b319415e0d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386621, encodeId=952f13866216f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=CheckMate-227 三年随访数据证实：欧狄沃（纳武利尤单抗）联合伊匹木单抗为一线转移性非小细胞肺癌患者带来持久且长期的生存获益, objectType=article, longId=194156, objectId=071f1941562d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=071f1941562d, replyNumber=0, likeNumber=46, createdTime=2020-05-16, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=071f1941562d, moduleTitle=CheckMate-227 三年随访数据证实：欧狄沃（纳武利尤单抗）联合伊匹木单抗为一线转移性非小细胞肺癌患者带来持久且长期的生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=071f1941562d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386620, encodeId=88d31386620d7, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌, objectType=article, longId=194130, objectId=0b9d19413073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b9d19413073, replyNumber=0, likeNumber=76, createdTime=2020-05-15, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b9d19413073, moduleTitle=FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b9d19413073)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386619, encodeId=07311386619b4, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Cell Death Dis：肺特异性寡转移性结直肠癌的遗传轨迹和肿瘤微环境, objectType=article, longId=194129, objectId=4dfd1941295a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dfd1941295a, replyNumber=0, likeNumber=69, createdTime=2020-05-15, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dfd1941295a, moduleTitle=Cell Death Dis：肺特异性寡转移性结直肠癌的遗传轨迹和肿瘤微环境, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4dfd1941295a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386618, encodeId=8d5c13866188a, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=FDA加速批准诺华的MET抑制剂Tabrecta，用于治疗METex14突变的转移性非小细胞肺癌, objectType=article, longId=193801, objectId=4a9d19380176, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a9d19380176, replyNumber=0, likeNumber=61, createdTime=2020-05-10, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a9d19380176, moduleTitle=FDA加速批准诺华的MET抑制剂Tabrecta，用于治疗METex14突变的转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a9d19380176)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386617, encodeId=ba9f138661ee7, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=TAVO联合KEYTRUDA治疗晚期转移性黑素瘤：总缓解率达41％，完全缓解率达36％, objectType=article, longId=193651, objectId=96f61936511b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96f61936511b, replyNumber=0, likeNumber=69, createdTime=2020-05-09, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96f61936511b, moduleTitle=TAVO联合KEYTRUDA治疗晚期转移性黑素瘤：总缓解率达41％，完全缓解率达36％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96f61936511b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

转移性

2020-05-29

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

PD-L1单抗Bavencio：正在欧洲接受审查以治疗转移性尿路上皮癌

2020-06-24

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Fruquintinib治疗转移性结直肠癌：美国FDA授予快速通道称号

2020-06-20

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

FDA授予伊立替康脂质体（ONIVYDE）快速通道指定，用于转移性胰腺癌的一线联合治疗

2020-06-19

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

转移性小细胞肺癌（SCLC）新药Zepzelca（lurbinectin）已获批准

2020-06-18

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Zepzelca在美国获批，二线治疗转移性小细胞肺癌

2020-06-18

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

罗氏的Tecentriq/Avastin组合获得美国批准——用于无法切除或转移性肝癌的免疫疗法

2020-06-06

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

FDA批准CYRAMZA（ramucirumab）一线治疗转移性EGFR突变非小细胞肺癌

2020-06-03

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

NEJM：奥拉帕尼治疗转移性去势耐药性前列腺癌

2020-05-30

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Brit J Cancer：性别在转移性结直肠癌先天性和适应性免疫微环境中的作用

2020-05-28

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet Oncol：派姆单抗联合疗法一线治疗HER2阳性转移性食管胃癌

2020-05-27

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者

2020-05-25

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌

2020-05-21

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

肺癌一线免疫治疗！BMS明星免疫组合Opdivo+Yervoy获美国FDA批准第5个适应症，治疗转移性非小细胞肺癌患者!

2020-05-20

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet：Atezolizumab联合铂化疗一线治疗转移性尿路上皮癌

2020-05-17

爆笑小医 (审核中...)

前往app查看评论内容

#转移性#

CheckMate -9LA临床试验数据积极！欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗显著提高一线转移性非小细胞肺癌患者总生存

2020-05-16

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

CheckMate-227 三年随访数据证实：欧狄沃（纳武利尤单抗）联合伊匹木单抗为一线转移性非小细胞肺癌患者带来持久且长期的生存获益

2020-05-16

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌

2020-05-15

docwu2019 (审核中...)

前往app查看评论内容

#转移性#

Cell Death Dis：肺特异性寡转移性结直肠癌的遗传轨迹和肿瘤微环境

2020-05-15

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

FDA加速批准诺华的MET抑制剂Tabrecta，用于治疗METex14突变的转移性非小细胞肺癌

2020-05-10

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

TAVO联合KEYTRUDA治疗晚期转移性黑素瘤：总缓解率达41％，完全缓解率达36％

2020-05-09

科室
- - 订阅+
  - 更多科室
工具
服务